Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Iris-claw Artiflex vs posterior chamber ICL phakic intraocular lenses for treatment of high myopia

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Phakic IOLs II

Session Date/Time: Monday 12/09/2016 | 09:30-11:00

Paper Time: 10:50

Venue: Poster Village: Pod 2

First Author: : R.Leite PORTUGAL

Co Author(s): :    T. Monteiro   N. Franqueira   F. Faria Correia   F. Vaz     

Abstract Details

Purpose:

To compare refractive outcomes and secondary complications following implantation of iris-claw phakic intraocular lens (pIOL) Artiflex® and posterior chamber ICL® V4c pIOL during a 24 months follow-up to correct high myopia.

Setting:

Department of Ophtalmology, Hospital de Braga, Portugal

Methods:

We retrospectively analysed 39 eyes of 27 patients who underwent implantation of Artiflex pIOL and 38 eyes of 21 patients who underwent implantation of ICL pIOL. Main outcomes measures evaluated during follow-up (6, 12 and 24 months after surgery): manifest refraction, corrected and uncorrected distance visual acuity (CDVA and UDVA), endothelial cell density and corneal topography were evaluated. Thibos vectorial analysis was performed to evaluate astigmatism.

Results:

Mean age was 33.7±6.73 and 31.5±7.42 for Artiflex and ICL groups respectively. For Artiflex mean preoperative manifest sphere and cylinder was -6.67D ±1.63 and -1.36±0.70, respectively; for ICL was -6.36D±3.27 and -0.94±1.02. A clinically significant hypocorrection was predicted for Artiflex for myopia higher than -12.0D. Vectorial astigmatism analysis showed a postoperative J0, J45 and B different from zero with Artiflex. The percentage of patients with CDVA and UDVA of 20/20 or better was superior with ICL during all follow-up (p=0.15 and 0.19, respectively). The efficacy and safety were higher in ICL group (p>0,05). Surgically induced astigmatism was -0.52D with Artiflex and -0.18D with ICL. Endothelial cell loss was higher with Artiflex (p>0,05).

Conclusions:

Compared to iris-claw Artiflex IOL, posterior chamber ICL® V4C model showed better visual and refractive outcomes, and also better predictability, efficacy and safety correcting high myopia, with or without astigmatism, during a 24 month follow-up.

Financial Disclosure:

NONE

Back to previous